



Review Radial Access for Coronary Angiography Carries Fewer Complications Compared with Femoral Access: A Meta-Analysis of Randomized Controlled Trials

Gani Bajraktari ^{1,2,3,4,*}, Zarife Rexhaj ², Shpend Elezi ^{2,3}, Fjolla Zhubi-Bakija ², Artan Bajraktari ^{1,2}, Ibadete Bytyçi ^{1,2}, Arlind Batalli ^{2,3} and Michael Y. Henein ¹

- ¹ Department of Public Health and Clinical Medicine, Umeå University, 90187 Umeå, Sweden; artanbajraktari@hotmail.com (A.B.); ibytyci@hotmail.com (I.B.); michael.henein@umu.se (M.Y.H.)
- ² Clinic of Cardiology, University Clinical Centre of Kosova, 10000 Prishtina, Kosovo; dr.zariferexhaj@gmail.com (Z.R.); selezi@hotmail.com (S.E.); fjolla.zhubi@gmail.com (F.Z.-B.); arlindbatalli@hotmail.com (A.B.)
- ³ Medical Faculty, University of Prishtina "Hasan Prishtina", 10000 Prishtina, Kosovo
- ⁴ UBT College, 10000 Prishtina, Kosovo
- * Correspondence: gani.bajraktari@umu.se

Abstract: Background and Aim: In patients undergoing diagnostic coronary angiography (CA) and percutaneous coronary interventions (PCI), the benefits associated with radial access compared with the femoral access approach remain controversial. The aim of this meta-analysis was to compare the short-term evidence-based clinical outcome of the two approaches. Methods: The PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched for randomized controlled trials (RCTs) comparing radial versus femoral access for CA and PCI. We identified 34 RCTs with 29,352 patients who underwent CA and/or PCI and compared 14,819 patients randomized for radial access with 14,533 who underwent procedures using femoral access. The follow-up period for clinical outcome was 30 days in all studies. Data were pooled by meta-analysis using a fixed-effect or a random-effect model, as appropriate. Risk ratios (RRs) were used for efficacy and safety outcomes.Results: Compared with femoral access, the radial access was associated with significantly lower risk for all-cause mortality (RR: 0.74; 95% confidence interval (CI): 0.61 to 0.88; p = 0.001), major bleeding (RR: 0.53; 95% CI:0.43 to 0.65; p < 0.00001), major adverse cardiovascular events (MACE)(RR: 0.82; 95% CI: 0.74 to 0.91; p = 0.0002), and major vascular complications (RR: 0.37; 95% CI: 0.29 to 0.48; p < 0.00001). These results were consistent irrespective of the clinical presentation of ACS or STEMI. Conclusions: Radial access in patients undergoing CA with or without PCI is associated with lower mortality, MACE, major bleeding and vascular complications, irrespective of clinical presentation, ACS or STEMI, compared with femoral access.

Keywords: femoral; radial; coronarography; PCI; acute coronary syndrome; stable coronary artery disease

1. Introduction

Patients with coronary artery disease (CAD) typically present with chest pain or shortness of breath. In patients with stable or unstable CAD, coronary angiography (CA), as the gold standard for detection and assessment of coronary artery stenoses, is performed, according to current clinical guidelines [1]. Revascularization therapy is indicated in patients with acute coronary syndrome (ACS) and in those with confirmed significant coronary stenosis not responding to optimal medical therapy or demonstrating marked limitation of physical activity [1]. Percutaneous coronary intervention (PCI), as an alternative to coronary artery bypass graft surgery, was introduced in the 1990s and is currently performed as a revascularization tool in the majority of patients with CAD [2]. The traditional approach for CA and PCI has been through the femoral artery, owing to its



Citation: Bajraktari, G.; Rexhaj, Z.; Elezi, S.; Zhubi-Bakija, F.; Bajraktari, A.; Bytyçi, I.; Batalli, A.; Henein, M.Y. Radial Access for Coronary Angiography Carries Fewer Complications Compared with Femoral Access: A Meta-Analysis of Randomized Controlled Trials. *J. Clin. Med.* 2021, *10*, 2163. https://doi.org/ 10.3390/jcm10102163

Academic Editor: Nazario Carrabba

Received: 24 March 2021 Accepted: 6 May 2021 Published: 17 May 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). large caliber, which provides easy access [3]. Bleeding is the most common complication of PCI and is associated with poor clinical outcomes [4,5]. However, since 1989, the transradial approach has been attempted as an alternative to femoral access [6] and has resulted in less access-site bleeding due to the easily compressible radial artery; the superficial anatomy of the radial artery also encourages early patient discharge after procedures [7]. However, the radial approach for diagnostic CA and PCI requires a longer learning curve and higher procedure volumes in order to achieve adequate and safe skills. Over the last decades, several published randomized clinical trials (RCTs) assessed the value of the radial compared with the femoral approach in patients undergoing diagnostic CA and PCI with respect to residual ischemic, bleeding, and combined outcomes. The results of these RCTs remain controversial.

Therefore, in this meta-analysis, we aimed to provide a comprehensive and quantitative assessment of the available evidence from RCTs in comparing the clinical outcome of the radial and femoral approach to CA for diagnostic and interventional objectives.

2. Methods

Following the 2009 guidelines for systematic reviews and meta-analysis, we used PRISMA [8]. Based on the study design (meta-analysis), there was no need to request Institutional Review Board (IRB) approval or patient informed consent.

2.1. Search Strategy

We systematically searched PubMed-Medline, EMBASE, Scopus, Google Scholar, the Cochrane Central Registry of Controlled Trials and ClinicalTrial.gov, up to June 2020, using the following key words: ('femoral' OR 'transfemoral') AND ('radial' OR 'transradial') AND ('percutaneous coronary intervention' OR 'PCI' OR 'coronarography' OR 'coronary angiography') AND ('randomized controlled trial' OR 'RCT'). Additional searches for potential trials included the references of review articles on that subject and the abstracts from selected congresses: scientific sessions of the European Society of Cardiology (ESC), the American Heart Association (AHA), the American College of Cardiology (ACC) and the European Society of Atherosclerosis (EAS). The literature search was limited to articles published in English. Two reviewers (GB and FZB) independently evaluated each article separately. No filters were applied. The remaining articles were obtained in fulltext and assessed again by the same two researchers, who evaluated each article independently and carried out data extraction and quality assessment. Disagreements were resolved by discussion with a third party (MYH).

2.2. Eligibility Criteria

Studies eligible for inclusion were those fulfilling the following criteria: (1) RCTs comparing the clinical outcome of the radial and femoral approach to CA for diagnostic and interventional objectives; (2) minimum follow-up of in-hospital stay; and (3) full-text studies published in peer-reviewed journals in English.Observational and unpublished studies were not included in the meta-analysis.

2.3. Data Extraction

Eligible studies were reviewed, and the following data were abstracted: (1) first author's name; (2) year of publication; (3) name of clinical trial; (4) country where the study was performed; (5) number of centers; (6) study design; (7) number of patients in the two groups of unprotected LMCA revascularization; (8) follow-up duration and (9) clinical outcome data and number of events in both groups.

2.4. Clinical Outcomes and Definitions

The clinical outcomes of interest were evaluated at the longest available follow-up time(up to 30 days). There were 2 primary endpoints: all-cause mortality and major bleeding. Secondary efficacy and safety outcomes were myocardial infarction, stroke,

the composite of major adverse cardiovascular events (MACE), and major vascular complications. The definition of MACE included the composite of death, stroke and myocardial infarction. Major bleeding was defined according to the scales used in each study [9,10], whereas major vascular complications were adjudicated according to the study definition or as hematoma >5 cm or pseudoaneurysm, if not reported in each study.

2.5. Quality Assessment

Risk of bias assessment in the included studies was evaluated by the same investigators for each study and was performed systematically using the Cochrane quality assessment tool for RCTs [11]. The Cochrane tool has 7 criteria for quality assessment: random sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other potential sources of bias. The risk of bias in each study was classified as "low", "high" or "unclear".

2.6. Statistical Analysis

We performed the pooled analyses of clinical outcomes and treatment effects using the Cochrane Collaborative software, RevMan 5.3.5 (the Nordic Cochrane Center, the Cochrane Collaboration, 2014, Copenhagen, Denmark) [12]. A two-tailed *p* value < 0.05 was considered as significant. The baseline characteristics are reported as median and range. Mean and standard deviation (SD) values were estimated using the method described by Hozo et al. [13]. Analysis is presented in forest plots. Meta-analyses were performed with a fixed-effect model and random effect model, based on the encountered heterogeneity. Heterogeneity between studies was assessed using the Cochrane Q test and I² index. As a guide, I² < 25% indicated low, 25–50% moderate, and >50% high heterogeneity [14]. Publication bias was assessed using visual inspection of funnel plots and Egger's test.

3. Results

3.1. Search Results and Trial Flow

Of the 334 articles identified in the initial search, 100 studies were screened as potentially relevant, but following critical scrutiny, only 34 RCTs [15–48] were considered appropriate and were included in this meta-analysis (Figure 1). The main characteristics of the included studies are reported in Supplementary Table S1.



Figure 1. PRISMA study selection flow chart.

3.2. Characteristics of Included Patients

Of the 29,352 patients eligible for analysis, 14,819 patients were assigned to the radial approach and 14,533 were assigned to the femoral approach. Random effect risk ratios were used for efficacy and safety outcomes. The mean age of patients was 59 years.

4. Outcomes of Patients in the Whole Group

4.1. Primary Clinical Outcomes

4.1.1. All-Cause Mortality

All-cause mortality was reported in 33/34 included trials. All-cause mortality occurred in 191 patients (1.3%) assigned to the radial approach and in 262 patients (1.8%) assigned to the femoral approach at the latest follow-up. All-cause mortality was lower in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.74; 95% CI: 0.61 to 0.88; p = 0.001, Figure 2A). There was no evidence for heterogeneity across the RCTs (I² = 0%).

A) All-cause mortality

	Radi	al	Ferno	ral		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
ACCESS 1997	1	300	0	300	0.3%	3.00 [0.12, 73.35]	
Achenbach 2008	0	152	0	155		Not estimable	
Akturk 2014	0	408	1	428	0.3%	0.35 [0.01, 8.56]	
Andrade 2017	0	120	0	120		Not estimable	
Benit 1997	0	50	0	55		Not estimable	
Bhat 2017	0	200	1	200	0.3%	0.33 [0.01, 8.13]	
Brueck 2009	0	512	0	512		Not estimable	
Cooper 1999	0	101	0	100		Not estimable	
FARMI 2007	3	57	3	57	1.4%	1.00 [0.21, 4.75]	
FERARI 2017	1	200	1	200	0.4%	1.00 [0.06, 15.88]	
Gan 2009	2	90	3	105	1.1%	0.78 [0.13, 4.55]	
Hou 2010	4	100	5	100	2.1%	0.80 [0.22, 2.89]	
Mann 1998	0	68	0	77		Not estimable	
MATRIX 2015	66	4197	91	4207	34.4%	0.73 [0.53, 1.00]	
OCEAN RACE 2014	1	52	3	51	0.7%	0.33 [0.04, 3.04]	
OCTOPLUS 2004	8	192	6	185	3.1%	1.28 [0.45, 3.63]	
RADIAL-AMI 2005	0	25	1	25	0.3%	0.33 [0.01, 7.81]	
RADIAL-CABG 2013	0	64	0	64		Not estimable	
RADIAMI 2009	0	50	1	50	0.3%	0.33 [0.01, 7.99]	
RADIAMI II 2011	0	49	0	59		Not estimable	
Reddy 2004	0	25	0	25		Not estimable	
RIFLE-STEACS 2012	26	500	46	501	15.7%	0.57 [0.36, 0.90]	
RIVAL 2011	44	3507	51	3514	21.2%	0.86 [0.58, 1.29]	
SAFARI-STEMI 2020	17	1136	15	1156	7.1%	1.15 [0.58, 2.30]	
SAFE-PCI 2018	0	330	3	310	0.4%	0.13 [0.01, 2.59]	• • • • • • • • • • • • • • • • • • • •
Santas et al, 2009	1	666	2	332	0.6%	0.25 [0.02, 2.74]	
Scherthaner 2018	1	125	3	125	0.7%	0.33 [0.04, 3.16]	
Slagboom 2005	0	322	1	322	0.3%	0.33 [0.01, 8.15]	
STEMI-RADIAL 2013	8	348	13	359	4.5%	0.63 [0.27, 1.51]	
SURF 2019	1	679	2	662	0.6%	0.49 [0.04, 5.36]	
TEMPURA 2003	4	77	6	72	2.3%	0.62 [0.18, 2.12]	
Wang 2012	0	60	1	59	0.3%	0.33 [0.01, 7.89]	
Yan 2008	3	57	3	46	1.4%	0.81 [0.17, 3.81]	
Ziakas 2010	0	0	0	0		Not estimable	
Total (95% CI)		14819		14533	100.0%	0.74 [0.61, 0.88]	•
Total events	191		262				
Heterogeneity: Tau ² = 0	.00; Chi ² =	= 10.30,	df = 23 (F	= 0.99)	; l² = 0%		
Test for overall effect: Z	= 3.27 (P	= 0.001)				Favours RADIAL Favours FEMORAL
B) Major bl	eedin	σ					

Radial Femoral **Risk Ratio Risk Ratio** Weight M-H, Random, 95% CI 0.5% 0.11 [0.01, 2.05] 1.0% 0.20 [0.02, 1.73] 0.4% 0.20 [0.01, 2.05] Study or Subgroup ents Total M-H, Random, 95% Cl ents ACCESS 1997 Achenbach 2008 Akturk 2014 Andrade 2017 0.5% 1.0% 0.4% 300 155 428 120 359 300 152 408 120 1 2 5 2 0 0 0.35 [0.01, 8.56] 1.00 [0.14, 6.98] 1.2% 4.3% 1.4% 348 50 0 26 Benit 1997 0.20 [0.08, 0.51] Bhat 2017 3 55 0.73 [0.13, 4.21] Brueck 2009 0 Not estimable Cooper 1999 0 Not estimable Cooper 1999 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRIX 2015 OCEAN RACE 2014 OCTOPLUS 2004 FADIAL AMI 2005 Not estimable 1.00 (0.21, 4.75) 0.33 (0.14, 0.82) 0.23 (0.01, 4.79) 0.14 (0.01, 2.73) Not estimable 0.58 (0.51, 0.66) 1.47 (0.26, 8.44) 0.25 (0.02, 2.71) Not estimable 57 200 90 100 1.8% 4.6% 0.5% 0.5% 57 3600 200 105 100 18 2 3 0 4197 0 4207 350 24.2% 1.4% 0.8% 606 52 140 51 70 RADIAL-AMI 2005 0 25 0 25 Not estimable RADIAL-CABG 2013 03 0 50 49 0 0 0 Not estimable 50 59 0 RADIAMI 2009 2.5% 2.8% 0.43 [0.12, 1.56] RADIAMI II 2011 Reddy 2004 RIFLE-STEACS 2012 RIVAL 2011 SAFARI-STEMI 2020 SAFE-PCI 2018 Santas et al, 2009 Scherthaner 2018 Slagboom 2005 STEMIR-RDIAL 2013 RADIAMI II 2011 6 0.80 [0.24, 2.68] Not estimable 0 Not estimable 0.64 [0.28, 1.47] 0.85 [0.70, 1.02] 0.68 [0.31, 1.50] 0.37 [0.02, 8.94] 0.73 [0.12, 4.32] 0.33 [0.01, 8.10] 0.42 [0.21, 0.84] 0.20 [0.08, 0.51] 500 3507 1136 104 666 125 322 14 217 15 1 5.3% 21.8% 5.7% 0.4% 1.4% 0.4% 7.1% 4.3% 3.8% 501 3514 1156 115 322 125 322 183 10 0 3 0 11 5 0 26 26 14 72 7 348 679 772 STEMI-RADIAL 2013 359 0.20 [0.08, 0.51] SURF 2019 662 0.35 [0.13, 0.96] TEMPURA 2003 0 59 Not estimable Wang 2012 Yan 2008 Ziakas 2010 60 57 27 1.0% 0.14 [0.02, 1.11] n 46 29 0.4% 0.21 [0.01, 4.27] ň ÷ Total (95% CI) 14641 13551 100.0% 0.53 [0.43, 0.65] ٠ Total events 607 1088 Heterogeneity: Tau² = 0.05; Chi² = 36.29, df = 26 (P 7 1088 Test for overall effect: Z = 5.84 (P < 0.00001)</td> 7 1088 0.09); I² = 28% 0.01 100 0.1 1 10 Favours RADIAL Favours FEMORAL

Figure 2. Risk of all-cause mortality (**A**) and major bleeding (**B**) at follow-up: radial vs. femoral, in whole group of patients.

4.1.2. Major Bleeding

Major bleeding was reported in 29/34 included RCTs, having occurred in 607 patients (4.1%) assigned to the radial approach and in 1088 patients (8%) assigned to the femoral approach. Major bleeding was less frequent in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.53; 95% CI: 0.43 to 0.65; p < 0.00001, Figure 2B). The heterogeneity was moderate (I² = 28%).

4.2. Secondary Clinical Outcomes

4.2.1. MACE

MACE was reported in all 34 included RCTs. MACE occurred in 605 patients (5%) assigned to the radial approach and in 745 patients (6.2%) assigned to the femoral approach at the latest follow-up. MACE werefewer in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.82; 95% CI: 0.74 to 0.91; p = 0.0002, Figure 3A). There was no evidence for heterogeneity across the RCTs (I² = 0%).

A) MACE	Radi	al	Femo	ral		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
ACCESS 1997	20	300	16	300	2.6%	1.25 [0.66, 2.36]	
Achenbach 2008	0	152	5	155	0.1%	0.09 [0.01, 1.66]	·
Akturk 2014	3	408	4	428	0.5%	0.79 [0.18, 3.49]	
Andrade 2017	3	120	5	120	0.5%	0.60 [0.15, 2.45]	
Benit 1997	3	50	6	55	0.6%	0.55 [0.15, 2.08]	
Bhat 2017	0	200	1	200	0.1%	0.33 [0.01, 8.13]	
Brueck 2009	0	512	2	512	0.1%	0.20 [0.01, 4.16]	·
Cooper 1999	0	101	1	99	0.1%	0.33 [0.01, 7.93]	· · · · · · · · · · · · · · · · · · ·
FARMI 2007	7	57	7	57	1.1%	1.00 [0.37, 2.67]	
FERARI 2017	9	200	6	200	1.0%	1.50 [0.54, 4.14]	
Gan 2009	2	90	5	105	0.4%	0.47 [0.09, 2.35]	
Hou 2010	4	100	5	100	0.6%	0.80 [0.22, 2.89]	
Mann 1998	0	68	0	77		Not estimable	
MATRIX 2015	381	4197	437	4207	62.8%	0.87 [0.77, 1.00]	-
OCEAN RACE 2014	5	52	6	51	0.8%	0.82 [0.27, 2.51]	
OCTOPLUS 2004	7	192	17	185	1.5%	0.40 [0.17, 0.93]	
RADIAL-AMI 2005	0	25	1	25	0.1%	0.33 [0.01, 7.81]	
RADIAL-CABG 2013	0	63	0	64		Not estimable	
RADIAMI 2009	1	50	2	50	0.2%	0.50 [0.05, 5.34]	
RADIAMI II 2011	1	49	1	59	0.1%	1.20 [0.08, 18.76]	
Reddy 2004	0	25	0	25		Not estimable	
RIFLE-STEACS 2012	36	500	57	501	6.7%	0.63 [0.42, 0.94]	
RIVAL 2011	26	955	46	1003	4.8%	0.59 [0.37, 0.95]	
SAFARI-STEMI 2020	45	1136	39	1156	6.0%	1.17 [0.77, 1.79]	
SAFE-PCI 2018	4	179	6	203	0.7%	0.76 [0.22, 2.64]	
Santas et al, 2009	7	666	9	332	1.1%	0.39 [0.15, 1.03]	
Scherthaner 2018	1	125	6	125	0.2%	0.17 [0.02, 1.36]	
Slagboom 2005	7	322	7	322	1.0%	1.00 [0.35, 2.82]	
STEMI-RADIAL 2013	12	348	15	359	1.9%	0.83 [0.39, 1.74]	
SURF 2019	3	679	7	662	0.6%	0.42 [0.11, 1.61]	
TEMPURA 2003	13	77	16	72	2.5%	0.76 [0.39, 1.47]	
Wang 2012	2	60	6	59	0.4%	0.33 [0.07, 1.56]	
Yan 2008	3	57	3	46	0.4%	0.81 [0.17, 3.81]	
Ziakas 2010	0	27	1	29	0.1%	0.36 [0.02, 8.41]	· · · · ·
Total (95% CI)		12142		11943	100.0%	0.82 [0.74, 0.91]	•
Total events	605		745				
Heterogeneity: Tau ² = 0	0.00; Chi ² =	25.57,	df = 30 (F	P = 0.70)	; l² = 0%		0.01 0.1 1
lest for overall effect: Z	= 3.73 (P	= 0.000	2)				Favours RADIAL Favours FE

B) Major vascular complications

	Radi	al	Femo	ral		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% Cl
ACCESS 1997	0	300	6	300	0.8%	0.08 [0.00, 1.36]	+	
Achenbach 2008	0	0	0	0		Not estimable		
Akturk 2014	7	408	31	428	7.1%	0.24 [0.11, 0.53]		
Andrade 2017	9	120	15	120	7.4%	0.60 [0.27, 1.32]		+
Benit 1997	0	50	3	55	0.7%	0.16 [0.01, 2.96]	+	
Bhat 2017	1	200	5	200	1.4%	0.20 [0.02, 1.70]	-	
Brueck 2009	3	512	19	512	3.8%	0.16 [0.05, 0.53]		
Cooper 1999	0	0	0	0		Not estimable		
FARMI 2007	2	57	11	57	2.8%	0.18 [0.04, 0.78]		
FERARI 2017	0	0	0	0		Not estimable		
Gan 2009	2	90	12	105	2.7%	0.19 [0.04, 0.85]		
Hou 2010	0	100	5	100	0.8%	0.09 [0.01, 1.62]	+	
Mann 1998	0	68	3	77	0.7%	0.16 [0.01, 3.07]	+	
MATRIX 2015	4	4197	15	4204	4.5%	0.27 [0.09, 0.80]		
OCEAN RACE 2014	0	0	0	0		Not estimable		
OCTOPLUS 2004	3	192	12	185	3.6%	0.24 [0.07, 0.84]		
RADIAL-AMI 2005	1	25	1	25	0.9%	1.00 [0.07, 15.12]		
RADIAL-CABG 2013	0	0	0	0		Not estimable		
RADIAMI 2009	5	50	8	50	4.8%	0.63 [0.22, 1.78]		
RADIAMI II 2011	8	49	12	59	7.1%	0.80 [0.36, 1.81]		
Reddy 2004	0	0	0	0		Not estimable		
RIFLE-STEACS 2012	1	500	2	501	1.1%	0.50 [0.05, 5.51]		
RIVAL 2011	49	3507	131	3514	17.1%	0.37 [0.27, 0.52]		-
SAFARI-STEMI 2020	37	1136	46	1156	14.4%	0.82 [0.54, 1.25]		
SAFE-PCI 2018	0	104	0	115		Not estimable		
Santas et al, 2009	0	670	4	335	0.8%	0.06 [0.00, 1.03]	•	
Scherthaner 2018	11	125	31	125	9.6%	0.35 [0.19, 0.67]		
Slagboom 2005	0	322	1	322	0.6%	0.33 [0.01, 8.15]		
STEMI-RADIAL 2013	1	348	3	359	1.2%	0.34 [0.04, 3.29]		
SURF 2019	2	679	7	662	2.4%	0.28 [0.06, 1.34]		
TEMPURA 2003	0	0	0	0		Not estimable		
Wang 2012	1	60	7	59	1.5%	0.14 [0.02, 1.11]		
Yan 2008	1	57	6	46	1.4%	0.13 [0.02, 1.08]		
Ziakas 2010	0	27	3	29	0.8%	0.15 [0.01, 2.83]	•	
Total (95% CI)		13953		13700	100.0%	0.37 [0.29, 0.48]		•
Total events	148		399					
Heterogeneity: Tau ² = 0	.07; Chi ² =	= 31.74,	df = 25 (F	P = 0.17	; I ² = 21%	, ,	0.01	01 1 10 100
Test for overall effect: Z	= 7.50 (P	< 0.000	01)				0.01	Favours RADIAL Favours FEMORAL

Figure 3. Cont.

C) Myocardial infarction

	Dadi	al	Forme	ral		Dick Datio	Diek Datio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H Random 95% CL	M-H Random 95% Cl
ACCESS 1997	10	300	q	298	21%	1 10 (0 45 2 68)	
Achenbach 2008	0	152	0	155	2.1 %	Not estimable	
Akturk 2014	0	408	0	428		Notestimable	
Andrade 2017	ő	120	ő	120		Notestimable	
Benit 1997	1	50	1	55	0.2%	1.10 (0.07, 17, 12)	
Bhat 2017	0	200	0	200	0.12.70	Not estimable	
Brueck 2009	3	512	4	512	0.7%	0.75 (0.17, 3.33)	
Cooper 1999	0	101	0	99		Not estimable	
FARMI 2007	1	57	1	57	0.2%	1.00 [0.06, 15.60]	
FERARI 2017	4	200	2	200	0.6%	2.00 [0.37, 10.80]	
Gan 2009	0	90	2	105	0.2%	0.23 [0.01, 4.79]	
Hou 2010	0	100	0	100		Not estimable	
Mann 1998	0	68	0	77		Not estimable	
MATRIX 2015	299	4197	330	4207	72.5%	0.91 [0.78, 1.06]	
OCEAN RACE 2014	0	0	0	0		Not estimable	
OCTOPLUS 2004	0	0	0	0		Not estimable	
RADIAL-AMI 2005	0	25	0	25		Not estimable	
RADIAL-CABG 2013	0	24	0	30		Not estimable	
RADIAMI 2009	1	50	0	50	0.2%	3.00 [0.13, 71.92]	
RADIAMI II 2011	0	49	0	59		Not estimable	
Reddy 2004	0	0	0	0		Not estimable	
RIFLE-STEACS 2012	6	500	7	501	1.4%	0.86 [0.29, 2.54]	
RIVAL 2011	60	3507	65	3514	13.6%	0.92 [0.65, 1.31]	-
SAFARI-STEMI 2020	20	1136	19	1156	4.2%	1.07 [0.57, 2.00]	
SAFE-PCI 2018	3	213	4	231	0.7%	0.81 [0.18, 3.59]	
Santas et al, 2009	0	0	0	0		Not estimable	
Scherthaner 2018	0	125	2	125	0.2%	0.20 [0.01, 4.12]	•
Slagboom 2005	8	322	8	322	1.8%	1.00 [0.38, 2.63]	
STEMI-RADIAL 2013	4	348	3	359	0.7%	1.38 [0.31, 6.10]	
SURF 2019	1	679	2	662	0.3%	0.49 [0.04, 5.36]	
TEMPURA 2003	0	77	0	72		Not estimable	
Wang 2012	1	60	3	59	0.3%	0.33 [0.04, 3.06]	
Yan 2008	0	57	0	46		Not estimable	
Ziakas 2010	0	U	0	U		Not estimable	
Tetal (OEV CI)		42727		42024	100.0%	0.0210.04 4.051	
Total (95% CI)	100	13/2/	400	13824	100.0%	0.92 [0.81, 1.05]	•
Total events	422	C 07 -	402	4.000	17 - 001		
Tect for overall effect: 7	0.00, CHE	- 5.07, 0	II = 10 (P	= 1.00),	1 = 0.30		n n n n n n n n n n n n n n n n n n n
		- 0.20\					
restrict overall enect 2	2 = 1.29 (P	= 0.20)					Favours RADIAL Favours FEMORAL
	2 = 1.29 (P	= 0.20)					Favours RADIAL Favours FEMORAL
D) Stroke	2 = 1.29 (P	= 0.20)					Favours RADIAL Favours FEMORAL
D) Stroke	2 = 1.29 (P Radia	= 0.20) al	Femo	ral		Risk Ratio	Favours RADIAL Favours FEMORAL
D) Stroke Study or Subgroup	Radia Events	= 0.20) al Total	Ferno Events	ral Total	Weight	Risk Ratio M-H, Random, 95% Cl	Favours RADIAL Favours FEMORAL Risk Ratio M-H, Random, 95% Cl
D) Stroke Study or Subgroup ACCESS 1997	Radia Events	= 0.20) al <u>Total</u> 300	Femo Events 0	ral Total 300	Weight	Risk Ratio M-H, Random, 95% CI Not estimable	Favours RADIAL Favours FEMORAL Risk Ratio M-H, Random, 95% Cl
D) Stroke Study or Subgroup ACCESS 1997 Achenbach 2008	Radia Events 0 0	= 0.20) al <u>Total</u> 300 152	Femo Events 0 1	ral Total 300 155	Weight 1.3%	Risk Ratio M-H, Random, 95% CI Not estimable 0.34 (0.01, 8.28)	Favours RADIAL Favours FEMORAL Risk Ratio M-H, Random, 95% CI
D) Stroke Study or Subgroup ACCESS 1997 Achenbach 2008 Akdurk 2014	Radia Events 0 0 0	= 0.20) al <u>Total</u> 300 152 408	Femo Events 0 1 1	ral Total 300 155 428	Weight 1.3% 1.2%	Risk Ratio M-H, Randorn, 95% CI Not estimable 0.34 (0.01, 8.28) 0.35 (0.01, 8.56)	Favours RADIAL Favours FEMORAL Risk Ratio M-H, Random, 95% Cl
D) Stroke Study or Subgroup ACCESS 1997 Achenbach 2008 Akdurk 2014 Andrade 2017	Radia Events 0 0 0 0	= 0.20) al <u>Total</u> 300 152 408 0	Fermo Events 0 1 1 0	ral Total 300 155 428 0	Weight 1.3% 1.2%	Risk Ratio M-H, Randorn, 95% CI Not estimable 0.34 (0.01, 8.26) 0.35 (0.01, 8.56) Not estimable	Favours RADIAL Favours FEMORAL Risk Ratio M-H, Random, 95% CI
D) Stroke Study or Subgroup ACCESS 1997 Achenbach 2008 Aldurk 2014 Andrade 2017 Benit 1997	Radia Events 0 0 0 0 0	al <u>Total</u> 300 152 408 0 50	Femo Events 0 1 1 0 0	ral Total 300 155 428 0 55	Weight 1.3% 1.2%	Risk Ratio M-H, Random, 95% CI Not estimable 0.34 [0.01, 8.28] 0.35 [0.01, 8.56] Not estimable Not estimable	Favours RADIAL Favours FEMORAL Risk Ratio M-H, Random, 95% CI
D) Stroke Study or Subgroup ACCESS 1997 Achenbach 2008 Akturk 2014 Andrade 2017 Benit 1997 Bhat 2017	Radia Events 0 0 0 0 0 0 0 0	al Total 300 152 408 0 50 200	Femo Events 0 1 1 0 0 0	ral Total 300 155 428 0 55 200	Weight 1.3% 1.2%	Risk Ratio M-H, Random, 95% CI Not estimable 0.35 (0.01, 8.28) Not estimable Not estimable Not estimable	Favours RADIAL Favours FEMORAL Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 Achenbach 2008 Akturk 2014 Andrade 2017 Benit 1997 Bhat 2017 Brueck 2009	Radia Events 0 0 0 0 0 0 0 0 0 0	al Total 300 152 408 0 50 200 512	Femo Events 0 1 1 0 0 0 1	ral 300 155 428 0 55 200 512	Weight 1.3% 1.2% 1.2%	Risk Ratio M.H. Random, 95% CI Not estimable 0.34 (0.01, 8.28) 0.35 (0.01, 8.56) Not estimable Not estimable 0.33 (0.01, 8.16)	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study or Subgroup ACCESS 1997 ACherbach 2008 Akturk 2014 Andrade 2017 Benit 1997 Bruekt 2009 Cooper 1999	Radia Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0	= 0.20) Total 300 152 408 0 50 200 512 101	Femoo Events 0 1 1 0 0 0 0 1 1	ral <u>Total</u> 300 155 428 0 55 200 512 99	Weight 1.3% 1.2% 1.2% 1.3%	Risk Ratio M.H. Randorn, 95% C1 Not estimable 0.35 [0.01, 8.56] Not estimable Not estimable 0.33 [0.01, 8.16] 0.33 [0.01, 7.93]	Favours RADIAL Favours FEMORAL Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Achenbach 2008 Akturk 2014 Andrade 2017 Benit 1997 Bhat 2017 Brueck 2009 Cooper 1999 FARMI 2007	E = 1.29 (P Radia Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	= 0.20) Total 300 152 408 0 50 200 512 101 0	Femoo Events 0 1 1 0 0 0 1 1 0	ral 300 155 428 0 55 200 512 99 0	Weight 1.3% 1.2% 1.2% 1.3%	Risk Ratio M.H. Random, 95% C1 Not estimable 0.34 (0.01, 8.28) 0.35 (0.01, 8.56) Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 7.93) Not estimable	Risk Ratio M-H, Random, 95% CI
D) Stroke Study of Subgroup ACCESS 1997 ACherbach 2008 Akturk 2014 Andrade 2017 Brint 1997 Bhat 2017 Brueck 2009 Cooper 1999 FARMI 2007 FERARI 2017	2 = 1.29 (P Radia Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	al <u>Total</u> 300 152 408 0 50 200 512 101 0 200	Fermor Events 0 1 1 0 0 0 1 1 0 2	ral Total 300 155 428 0 55 200 512 99 0 200	Weight 1.3% 1.2% 1.2% 1.3% 1.4%	Risk Ratio Not estimable 0.35 (0.01, 8.26) Not estimable Not estimable 0.33 (0.01, 8.56) Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 7.93) Not estimable 0.20 (0.01, 4.14)	Favours RADIAL Favours FEMORAL Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Acchenbach 2008 Akturk 2014 Andrade 2017 Benit 1997 Bhat 2017 Brunck 2009 Cooper 1999 FARMI 2007 FERARI 2017 Gan 2009	E = 1.29 (P Radia Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	al <u>Total</u> 300 152 408 0 50 50 50 512 101 0 200 90	Fermor Events 0 1 1 0 0 0 1 1 1 0 2 0	ral Total 300 155 428 0 55 200 512 99 0 200 105	Weight 1.3% 1.2% 1.2% 1.3% 1.4%	Risk Ratio M-H, Random, 95% CI 0.34 (0.01, 9.28) 0.35 (0.01, 9.26) Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) Not estimable 0.20 (0.01, 4.14) Not estimable	Risk Ratio M-H, Random, 95% CI
D) Stroke Study of Subgroup ACCESS 1997 Achenbach 2008 Adurk 2014 Andrade 2017 Benit 1997 Bhat 2017 Bruzek 2009 Cooper 1999 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010	E = 1.29 (P Radii Events 0 0 0 0 0 0 0 0 0 0 0 0 0	al Total 300 152 408 0 50 200 512 101 0 200 90 0	Femo Events 0 1 1 0 0 0 1 1 1 0 2 0 0 0	ral 300 155 428 0 55 200 512 99 0 200 105 0	Weight 1.3% 1.2% 1.2% 1.3% 1.4%	Risk Ratio Not estimable 0.35 (0.01, 8.26) Not estimable Not estimable Not estimable 0.33 (0.01, 8.26) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.14) Not estimable Not estimable Not estimable	Favours RADIAL Favours FEMORAL
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Atkink 2014 Andrade 2017 Benit 1997 Behat 2017 Brusek 2009 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1998	Radia Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	al Total 300 152 408 0 50 200 512 101 0 200 512 101 0 200 0 0 0 0 0 0 0	Femo Events 0 1 1 0 0 0 1 1 1 0 2 0 0 0 0 0 0 0	ral 300 155 428 0 55 200 512 99 0 200 105 200 105 0 0 0	Weight 1.3% 1.2% 1.2% 1.3% 1.4%	Risk Ratio M-I, Random, 95% CI 0.34 (001.8.28) 0.35 (001.8.28) Not estimable Not estimable 0.33 (001.8.16) 0.33 (001.8.16) 0.33 (001.7.9.3) Not estimable 0.20 (0.01.4.14) Not estimable Not estimable Not estimable Not estimable	Risk Ratio M-H, Random, 95% CI
D) Stroke Study or Subgroup ACCESS 1997 ACCESS 1997 ACCESS 1997 Achenbach 2008 Adurk 2014 Andrade 2017 Benit 1997 Bhat 2017 Bruzek 2009 Cooper 1999 FERARI 2017 FERARI 2017 Gan 2009 Hou 2010 Mann 1988 MATRIX 2015	Events Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	al Total 300 152 408 0 50 200 512 101 0 200 90 0 0 4197	Femo Events 0 1 0 0 0 0 1 1 0 2 0 0 0 0 0 0 0 0 0 0	ral 300 155 428 0 55 200 512 99 0 200 105 200 105 0 0 4207	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7%	Risk Ratio Not estimable 0.34 (0.01, 8.28) 0.35 (0.01, 8.56) Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) Not estimable 0.20 (0.01, 4.14) Not estimable Not estimable Not estimable	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Aturk 2014 Andrade 2017 Benit 1997 Behat 2017 Brueck 2009 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRIX 2015 OCEAN RACE 2014	E = 1.29 (P Radia Events 0 0 0 0 0 0 0 0 0 0 0 0 0	= 0.20) Total 300 152 408 0 50 200 512 101 0 200 90 0 4197 52	Fermo Events 0 1 1 0 0 0 1 1 1 0 2 0 0 0 0 0 0 16 1	ral Total 300 155 428 0 55 200 512 99 0 200 105 0 0 4207 51	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3%	Risk Ratio M-I, Randorn, 95% CI 0.34 (0.01.8.28) 0.35 (0.01.8.26) Not estimable Not estimable 0.33 (0.01.8.16) 0.33 (0.01.7.93) Not estimable 0.20 (0.01.4.14) Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable	Risk Ratio M-H, Random, 95% CI
D) Stroke Study or Subgroup ACCESS 1997 ACCESS 1997 ACCESS 1997 ACCESS 1997 Benit 1997 Benit 1997 Benit 1997 Benit 1997 Benit 2017 Benit 2017 Benit 2017 Benit 2017 Benit 2017 Gooper 1999 FERARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRIX 2015 OCTOPLUS 2004	E = 1.29 (P Radis Events 0 0 0 0 0 0 0 0 0 0 0 0 0	al Total 300 152 408 50 200 512 101 0 200 90 0 0 4197 52 0	Fermoo Events 0 1 1 0 0 0 1 1 0 2 0 0 0 0 0 16 1 0	ral Total 300 155 428 0 55 200 512 99 0 200 105 0 4207 105 0 4207 105 0 0 0 105 0 0 105 0 0 105 0 0 105 0 105 105	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3%	Risk Ratio M.H. Random, 95% CI Not estimable 0.35 (0.01, 8.26) Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.01, 8.16) Not estimable Not estimable 1.00 (0.50, 2.00) 1.96 (0.18, 20.97) Not estimable	Risk Ratio H-H, Random, 95% CI
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Aturk 2014 Andrade 2017 Bent 1997 Bhat 2017 Bruek 2009 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRIK 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-MAI 2005	E = 1.29 (P Radia Events 0 0 0 0 0 0 0 0 0 0 0 0 0	= 0.20) 1 Total 300 152 408 0 50 200 512 101 0 200 90 0 4197 52 0 25	Fermon Events 0 1 1 0 0 0 1 1 2 0 0 0 0 0 0 0 0 0 0 0	ral Total 300 155 428 0 55 200 512 99 0 200 105 0 4207 51 0 0 4207 51 0 200 200 105 55 200 200 200 200 200 200 20	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3%	Risk Ratio M-I, Randorn, 95% CI 0.34 (0.01.8.28) 0.35 (0.01.8.26) Not estimable Not estimable 0.33 (0.01.8.16) 0.33 (0.01.7.93) Not estimable 0.20 (0.01.4.14) Not estimable Not estimable 1.00 (0.50,2.00) 1.98 (0.18,20.97) Not estimable Not estimable	Risk Ratio M-H, Random, 95% CI
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 ACCESS 1997 ACCESS 1997 Aturk 2014 Andrade 2017 Benit 1997 Bhat 2017 Bhat 2018 Bhat 2017 Bhat 2017 B	Events Events 0 0 0 0 0 0 0 0 0 0 0 0 0	al <u>Total</u> 300 152 408 0 50 200 0 200 0 0 0 4197 52 0 4 252 24	Fermon Events 0 1 1 0 0 0 1 1 0 2 0 0 0 0 0 0 16 1 0 0 0 0 0 0 0 0 0 0 0	ral Total 300 155 428 0 55 200 512 99 0 200 105 0 200 105 0 4207 51 0 4207 51 0 200 30 200 20	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3%	Risk Ratio M.H. Random, 95% CI. Not estimable 0.35 (0.01, 8.26) Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) Not estimable Not estimable	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Atchenbach 2008 Atturk 2014 Andrade 2017 Bent 1997 Bhat 2017 Bruek 2009 Cooper 1999 FAFMI 2007 FERARI 2017 Gan 2009 Hou 2010 MATRIX 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-CABC 2013 RADIAL-CABC 2013	E = 1.29 (P Radii <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	al <u>Total</u> 300 152 408 0 512 101 0 200 90 0 0 0 4197 52 0 25 24 50 50 50 50 50 50 50 50 50 50	Fermon Events 0 1 1 0 0 0 1 1 1 0 2 0 0 0 0 0 0 0 0 1 6 1 0 0 0 0 1	ral Total 300 155 428 0 512 99 0 0 0 0 0 4207 51 0 4207 51 0 4207 51 0 55 51 0 55 55 55 55 55 55 55 55 55	Weight 1.3% 1.2% 1.2% 1.3% 26.7% 2.3% 1.3%	Risk Ratio M.H. Random, 95% CI Not estimable 0.35 (0.01, 8.26) Not estimable Not estimable 0.33 (0.01, 8.26) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 4.14] Not estimable Not estimable	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 ACCESS 1997 Achenbach 2008 Aturk 2014 Andrade 2017 Benit 1997 Bhat 2017 Benit 1997 Bhat 2017 Benit 1997 Brack 2009 Cooper 1999 FRARN 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1988 MATRIX 2015 RADIAL-ABI 2005 RADIAL-ABI 2005 RADIAL-ABI 2005 RADIAL-CABO 2013 RADIAMI 2001	Events 0 0 0 0 0 0 0 0 0 0 0 0 0	al <u>Total</u> 300 152 408 0 50 200 512 101 0 200 0 200 0 200 0 200 0 200 0 200 0 200 0 200 0 200 0 200 0 200 0 200	Femo Events 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0	ral Total 300 155 428 200 512 99 0 200 105 0 4207 61 0 4207 51 0 0 0 0 0 55 55 55 55 55 55	Weight 1.3% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 1.3%	Risk Ratio M.H. Random, 95% CI. Not estimable 0.35 (0.01, 8.28) 0.35 (0.01, 8.26) Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) Not estimable Not estimable 1.00 (0.50, 2.00) 1.96 (0.18, 20.97) Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable 0.33 (0.01, 7.99) 0.40 (0.02, 9.60)	Risk Ratio M-H, Random, 95% CI
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Atchenbach 2008 Atturk 2014 Andrade 2017 Bent 1997 Bhat 2017 Bruek 2009 Cooper 1999 FARMI 2007 FERARI 2017 Gan 2009 MATRIX 2015 OCEAN RACE 2014 OCTOPLUS 2004 MATRIX 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2019 RADIAM II 2011 Reday 2004	Radii <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	al <u>Total</u> 300 152 408 0 200 512 101 0 200 200 200 200 4197 52 24 50 4197 62 25 24 50 0 0 0 0 0 0 0 0 0 0 0 0 0	Fermon Events 0 1 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0	ral Total 300 155 428 0 512 99 0 200 105 50 0 0 4207 51 0 0 4207 51 0 0 25 30 50 50 50 0 0 0 0 0 0 0 0 0 0 0 0 0	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 1.3%	Risk Ratio N-H, Random, 95% CI Not estimable 0.34 (0.01, 8.26) Not estimable Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.20 (0.01, 4.14) Not estimable Not estimable	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 ACCESS 1997 Advarks 2014 Andrade 2017 Benit 1997 Bhat 2017 Berneck 2009 Cooper 1999 Brueck 2009 Cooper 1999 ERARN 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRIK 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-CABO 2013 RADIAMI 2005 RADIAL-CABO 2013 RADIAMI 2011 Reddy 2004 RIFLE-STEACS 2012	Radia Events 0 0 0 0 0 0 0 0 0 0 0 0 0	al Total 300 152 408 0 50 200 0 512 101 0 200 0 0 0 0 0 0 0 0 0 0 0 0	Fermio Events 0 1 1 0 0 0 0 1 1 1 2 2 0 0 0 0 1 1 1 1	ral Total 300 155 428 0 55 200 512 99 0 200 0 0 0 0 0 0 0 0 0 0 0 512 99 0 0 0 0 0 0 0 0 0 0 0 0 0	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 5.7%	Risk Ratio M.H. Random, 95% CI. Not estimable 0.35 (0.01, 8.56) Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.35 (0.01, 8.16) Not estimable Not estimable 0.40 (0.02, 9.60) Not estimable 1.34 (0.30, 5.94]	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Atchenbach 2008 Aturk 2014 Andrade 2017 Bent 1997 Bhat 2017 Bruek 2009 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRX 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-ABI 2005 RADIAL-ABI 2003 RADIAL-ABI 2003 RADIAL-ABI 2003 RADIAL-ABI 2003 RADIAMI II 2011 Reddy 2004 RIFLE-STEACS 2012	Radia <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	al <u>Total</u> 300 152 408 0 50 200 50 200 50 200 0 0 0 0 0 0 0 0 0 0 0 0	Fermon Events 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ral <u>Total</u> 3000 1555 4288 0 512 99 0 2000 1055 0 0 0 0 4207 511 0 0 0 0 0 0 0 555 300 0 512 99 0 0 0 515 512 99 0 0 0 515 512 99 0 0 0 515 512 99 0 0 0 515 512 99 0 0 0 0 515 512 99 0 0 0 0 0 0 0 0 0 0 0 0 0	Weight 1.3% 1.2% 1.2% 1.3% 1.3% 26.7% 2.3% 1.3% 5.7% 38.4%	Risk Ratio M.H, Random, 95% CI Not estimable 0.35 (0.01, 8.26) Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.00 (0.50, 2.00) 1.96 (0.18, 2.0.97) Not estimable Not estimable 0.33 (0.01, 7.99) 0.40 (0.02, 9.60) Not estimable 1.35 (0.76, 2.41)	Risk Ratio M-H, Random, 95% Cl
D) Stroke <u>Study of Subgroup</u> ACCESS 1997 ACCESS 1997 Acchenbach 2008 Akturk 2014 Andrade 2017 Benet 1997 Erack 2009 Cooper 1999 EraRN 2017 Erack 2009 Hou 2017 Benet 1997 EraRN 2017 Cooper 1999 Cooper 1999 Coo	Radia Events 0 0 0 0 0 0 0 0 0 0 0 0 0	al Total 300 152 408 0 50 200 0 0 0 0 0 0 0 0 0 0 0 0	Fermion Events 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ral <u>Total</u> 300 155 428 0 55 200 512 99 0 0 0 4207 51 0 4207 51 0 0 4207 51 25 30 0 428 0 55 512 99 0 0 428 512 512 99 0 0 428 512 512 99 0 105 512 99 0 105 512 99 0 105 512 99 0 105 512 99 0 105 512 99 0 105 512 99 0 105 512 99 0 105 512 99 0 105 512 105 105 105 105 105 105 105 105	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 5.7% 38.4% 1.5%	Risk Ratio M.H. Random, 95% CI 0.34 [0 01, 8, 28] 0.35 [0,01, 8, 26] 0.35 [0,01, 8, 26] Not estimable Not estimable 0.33 [0,01, 8, 16] 0.33 [0,01, 8, 16] Not estimable Not e	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Atchenbach 2008 Atturk 2014 Andrade 2017 Bent 1997 Bhat 2017 Brueck 2009 Cooper 1999 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1988 MATRIX 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-ANI 2005 RADIAL-ANI 2005 RADIAL-ANI 2005 RADIAL-ANI 2015 RADIAL-ANI 2013 RADIAMI II 2011 READJANI II 2011 SAFARI-STEMI 2020 SAFE-PCI 2018	Radii Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	at Total 300 152 408 0 510 200 512 101 0 200 0 0 0 0 0 0 0 0 0 0 0 0	Fermon Events 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ral Total 300 155 200 512 99 0 200 105 0 0 4207 511 0 0 4207 51 0 0 0 0 50 50 0 0 0 55 0 0 55 5 5 0 0 5 5 5 5 5 5 5 5 5 5 5 5 5	Weight 1.3% 1.2% 1.2% 1.3% 2.6.7% 2.3% 1.3% 5.7% 38.4% 11.5%	Risk Ratio M.H. Random, 95% CI Not estimable 0.35 (0.01, 8.26) Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.35 (0.01, 8.16) Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable 0.33 (0.01, 7.99) 0.40 (0.02, 9.60) Not estimable 1.34 (0.30, 5.94) 1.35 (0.76, 2.41) 2.24 (0.78, 6.42) Not estimable	Risk Ratio M-H, Random, 95% Cl
D) Stroke <u>Study of Subgroup</u> ACCESS 1997 ACCESS 1997 Aturk 2014 Andrade 2017 Bent 1997 Ehat 2017 Bruek 2009 Cooper 1999 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRIX 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-MB 2005 RADIAL-CABG 2013 RADIAL-CABG 2013	Radiki Events b 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1 Total 300 152 408 0 50 200 500 200 200 512 101 0 200 90 0 0 0 0 0 0 0 200 20	Fermio Events 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ral 3000 1555 428 0 552 2000 512 2000 512 0 0 0 0 0 0 0 4207 51 0 0 4207 51 300 559 0 559 0 551 301 428 300 428 300 428 428 428 428 428 428 428 428	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 38.4% 11.5%	Risk Ratio M-H, Randorn, 95% CI 0.34 [0 0.16, 9.28] 0.35 [0.01, 8.56] Not estimable Not estimable 0.33 [0.01, 8.16] 0.33 [0.01, 8.16] 0.33 [0.01, 8.16] 0.33 [0.01, 8.16] Not estimable Not estimable	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Access 1997 Aturk 2014 Andrade 2017 Bent 1997 Bhat 2017 Bruek 2009 Cooper 1999 FARMI 2007 FERARI 2017 Gan 2008 Hou 2010 Mann 1998 MATRIX 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-AMI 2005 RADIAL-AMI 2005 RADIAL-MI 2005 RADIAL-MI 2005 RADIAL-MI 2005 RADIAL-MI 2015 ACTOPLUS 2004 RADIAL-AMI 2005 RADIAL-MI 2015 SOLAD 2013 RADIAMI 2011 RADIAL-STEM 2013 RADIAL-STEM 2013 SAFAR-STEM 2020 SAFE-PCI 2018 Santas et al, 2009 Scherthaner 2018	Radii Events Events 0	al <u>Total</u> 3000 1522 408 00 512 101 0 2000 0 2000 0 2000 0 2000 0 0 2000 0 0 2000 0 0 2000 0 0 0 0 0 0 0 0 0 0 0 0	Fermon Events 0 1 1 1 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0	ral 3000 1555 428 0 512 99 0 2000 1055 0 0 0 0 0 0 0 0 0 0 0 0 51 0 0 51 0 0 50 0 0 0 0 0 0 0 0 0 0 0 0 0	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 5.7% 38.4% 11.5% 1.3%	Risk Ratio M.H. Random, 95% CI. Not estimable 0.35 (0.01, 8.26) Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable 1.00 (0.50, 2.00) 1.96 (0.18, 2.0.97) Not estimable Not estimable 1.34 (0.30, 5.94) 1.35 (0.76, 2.41) 2.34 (0.76, 6.42) Not estimable 0.33 (0.01, 8.10)	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 Atchenbach 2008 Atturk 2014 Andrade 2017 Bent 1997 Bhat 2017 Bruek 2009 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRIK 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-MB 2005 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL 2005 RADIAL-CABG 2013 RADIAL 2005 RADIAL-CABG 2013 RADIAL 2005 RADIAL 2005	Radii Radii Events 0 0 0	al <u>Total</u> <u>300</u> 152 408 0 500 200 512 408 0 500 200 0 0 0 0 0 0 0 0 0 0 0 0	Fermion Events 0 1 1 1 1 0 0 0 0 1 1 1 0 0 0 0 0 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 0 0 1 1 1 1 0 0 0 0 1 1 1 1 1 0 0 0 0 1	ral <u>Total</u> 300 155 220 55 200 512 99 0 200 0 200 0 200 0 0 200 0 512 99 90 0 200 0 5155 300 0 200 0 55 55 55 300 0 200 0 55 55 300 0 200 0 55 55 0 99 90 0 200 0 55 0 0 0 0 0 0 0 0 0 0 0 0 0	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3%	Risk Ratio MH, Random, 95% CI 0.34 [0 0.16, 9.28] 0.35 [0.01, 8.56] Not estimable Not estimable 0.33 [0.01, 8.16] 0.33 [0.01, 8.16] 0.33 [0.01, 8.16] 0.33 [0.01, 8.16] Not estimable Not estimable Not estimable 1.00 [0.50, 2.00] 1.96 [0.18, 20.97] Not estimable Not estimable Not estimable 1.35 [0.17, 9.99] 0.40 [0.02, 9.60] Not estimable 1.35 [0.17, 9.91] 0.40 [0.02, 9.60] Not estimable 1.35 [0.17, 9.91] 1.35 [0.76, 2.41] 2.24 [0.78, 6.42] Not estimable Not estimable 0.33 [0.01, 8.10] Not estimable	Risk Ratio M-H, Random, 95% Cl
D) Stroke <u>Study of Subgroup</u> ACCESS 1997 ACCESS 1997 ACCESS 1997 Achenbach 2008 Adurk 2014 Andrade 2017 Benit 1997 Bhat 2017 Benit 1997 Bhat 2017 Benit 1997 Bhat 2017 FERARI 2017 Cooper 1999 FERARI 2007 FERARI 2007 FERARI 2007 FERARI 2007 FERARI 2007 FERARI 2007 FERARI 2007 COOPE 1999 Hou 2010 Mann 1988 MATRIX 2015 OCCENT RACE 2014 OCCOPLUS 2004 RADIAL-ABI 2005 RADIAL-ABI 2005 RADIAL-ABI 2011 Reddy 2004 RIFLE-STEACS 2012 RIAL 2011 Santas et al, 2009 Scherthaner 2018 Slagboorn 2005 STEMI-RADIAL 2013	Radii Events 0 0 0	al <u>Total</u> 300 152 408 0 50 50 200 0 512 101 0 200 0 0 0 0 0 0 0 0 0 0 0 0	Fermon Events s Events s 1 1 1 1 1 1 1 1 1 1 1 1 1	ral <u>Total</u> 3000 155 428 200 00 105 50 00 00 4207 51 00 00 00 00 00 50 50 50 50 00 0	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 5.7% 38.4% 1.3% 1.3% 4.0%	Risk Ratio R.H. Random, 95% CI. Not estimable 0.34 (0.01, 8.26) Not estimable Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable 0.40 (0.50, 2.00) 1.96 (0.18, 2.0.97) Not estimable Not estimable 0.33 (0.01, 7.99) 0.40 (0.02, 9.60) Not estimable 0.33 (0.01, 8.10) Not estimable 0.33 (0.01, 8.10) Not estimable 0.33 (0.12, 8.10) Not estimable 0.33 (0.12, 8.10) Not estimable 0.33 (0.01, 8.10) Not estimable 0.69 (0.12, 4.09)	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 ACCESS 1997 Aturk 2014 Andrade 2017 Bent 1997 Bhat 2017 Bruzek 2009 FARMI 2007 FERARI 2017 Gong 2009 Hou 2010 Mann 1998 MATRK 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-ABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL-CABG 2013 RADIAL COS STEMFASTEMI 2020 SAFE-PCI 2018 Santas et al, 2008 STEMFARDIAL 2013 STEMFARDIAL 2013 STEMFARDIAL 2013 STEMFARDIAL 2013	Radii Radii Events 0 0 0	al <u>Total</u> 300 152 408 00 500 500 500 200 500 00 00 00 00 00 00 00 00	Femo Events 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ral <u>Total</u> 300 155 428 00 512 200 512 99 00 200 105 0 0 4207 51 0 0 4207 51 0 0 55 200 512 0 0 0 0 55 0 0 0 0 0 55 0 0 0 0 0 0 0 0 0 0 0 0 0	Weight 1.3% 1.2% 1.2% 1.3% 1.3% 26.7% 2.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3%	Risk Ratio M-H, Randorn, 95% CI 0.34 (0.01, 8.28) 0.35 (0.01, 8.28) 0.35 (0.01, 8.28) Not estimable 0.33 (0.01, 8.18) 0.33 (0.01, 7.93) Not estimable 0.20 (0.01, 8.16) 0.33 (0.01, 7.93) Not estimable Not estimable 1.00 (0.50, 2.00) 1.98 (0.18, 20.97) Not estimable 1.90 (0.17, 9.99) 0.33 (0.01, 7.99) 0.33 (0.01, 7.99) 1.35 (0.76, 2.41) 2.24 (0.76, 2.41) 2.24 (0.76, 2.41) 2.34 (0.30, 5.94) 1.35 (0.76, 2.41) 2.34 (0.30, 8.10) Not estimable 0.63 (0.01, 8.10) Not estimable 0.63 (0.01, 7.96) 0.33 (0.01, 7.96) 0.33 (0.01, 7.96)	Risk Ratio M-H, Random, 95% CI
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 ACCESS 1997 Achenbach 2008 Adurk 2014 Andrade 2017 Benit 1997 Bhat 2017 Benit 1997 Bhat 2017 Benit 1997 ERARI 2007 FERARI 2017 FERARI 2017 FERARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRIX 2016 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-CABO 2013 RADIAMI 2005 RADIAMI 2005 RADIAMI 2001 RELE-STEACS 2012 RIVAL 2011 SAFARI-STEMI 2020 SAFEP-CI 2018 Santas et al. 2009 Scherthaner 2018 SUBF 2019 TEMPURA 2003	Radii Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	al <u>Total</u> 300 152 408 00 50 200 90 0 200 90 0 200 90 0 200 90 0 200 90 0 200 90 0 200 90 0 200 90 0 200 0 122 101 102 102 102 1	Fermio 0 0 1 1 1 1 0 0 1 1 0 0 0 1 1 1 0 0 0 0 0 1 1 1 0 0 0 1 1 1 200 0 3 200 1 1 0 3 3 1 0 3 1 0	ral <u>Total</u> 3000 1555 428 2000 552 999 0 2000 1055 512 999 0 2000 1055 512 999 0 2000 1055 512 999 0 2000 1055 512 999 0 2000 1055 512 512 512 512 512 512 512 5	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 5.7% 38.4% 1.3% 1.3% 4.0% 1.2%	Risk Ratio Not estimable 0.34 (0.01, 8.28) 0.35 (0.01, 8.26) Not estimable Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.30 (0.01, 8.16) 0.30 (0.01, 8.16) 0.40 (0.05, 0.20) 1.96 (0.18, 20.97) Not estimable Not estimable Not estimable 0.33 (0.01, 7.96) 0.40 (0.02, 9.60) Not estimable Not estimable 0.33 (0.01, 7.96) Not estimable 0.33 (0.01, 8.10) Not estimable 0.35 (0.01, 8.10)	Risk Ratio M-H, Random, 95% Cl
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 ACCESS 1997 Aturk 2014 Andrade 2017 Bent 1997 Bhat 2017 Bruek 2009 Cooper 1999 FARMI 2007 FERARI 2017 Gan 2009 Hou 2010 MATRIX 2015 OCEAN RACE 2014 OCTOPLUS 2004 MATRIX 2015 OCEAN RACE 2014 OCTOPLUS 2004 RADIAL-ABG 2013 RADIAMI 2005 RADIAL-CABG 2013 RADIAMI 2005 RADIAL-CABG 2013 RADIAMI 2005 RADIAL-CABG 2013 RADIAMI 2005 RADIAL-CABG 2013 RADIAMI 2005 RADIAMI 2005 SCIENTRADIAL 2003 SCIENTRADIAL 2013 SCIENTRADIAL 2013 SCIENTRADIAL 2013 STEMI-RADIAL 2013 STEMI-RADIAL 2013 STEMI-RADIAL 2013 STEMI-RADIAL 2013 STEMI-RADIAL 2013 STEMI-RADIAL 2013 STEMI-RADIAL 2013 STEMI-RADIAL 2013 STEMI-RADIAL 2013 SCIENTRADIAL 2013	Radii Events 0 0 0	al Total 300 152 408 0 500 512 101 0 200 512 101 0 200 200 512 101 0 200 0 0 0 0 0 0 0 0 0 0 152 408 0 0 512 408 0 0 512 408 0 0 512 408 0 0 512 408 0 0 512 408 0 0 512 408 0 0 512 408 0 0 0 512 408 0 0 512 408 0 0 0 512 408 0 0 0 0 0 0 0 0 0 0 0 0 0	Femo Events 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ral Total 300 155 428 0 50 200 200 200 0 0 0 0 0 0 0 0 0 0 0 0	Weight 1.3% 1.2% 1.3% 1.3% 26.7% 2.3% 1.3% 5.7% 38.4% 11.5% 1.3% 4.0% 1.2%	Risk Ratio M-I, Random, 95% CI 0.34 (0.01.8.28) 0.35 (0.01.8.28) 0.35 (0.01.8.26) Not estimable Not estimable 0.33 (0.01.8.16) 0.33 (0.01.7.93) Not estimable 0.20 (0.01.7.93) Not estimable Not estimable 1.00 (0.50,2.00) 1.98 (0.18,20.97) Not estimable Not estimable 0.33 (0.01.7.99) 0.40 (0.02,9.60) Not estimable 1.35 (0.17,8,241) 2.24 (0.78,6.42) 1.35 (0.76,2.41) 2.24 (0.78,6.42) Not estimable 0.33 (0.01,8.10) Not estimable 0.33 (0.01,8.10) Not estimable 0.33 (0.01,7.99) Not estimable 0.33 (0.01,7.91) Not estimable 0.33 (0.01,7.95) Not estimable 0.33 (0.01,7.95) Not estimable 0.33 (0.01,7.95) Not estimable 0.33 (0.01,7.95) Not estimable Not estimable	Risk Ratio M-H, Random, 95% CI
D) Stroke Study of Subgroup ACCESS 1997 ACCESS 1997 ACCESS 1997 ACCESS 1997 Advark 2014 Andrade 2017 Benit 1997 Bhat 2017 Benit 1997 Bhat 2017 EFRARI 2017 Gan 2009 Hou 2010 Mann 1998 MATRIX 2015 CEAN RACE 2014 OCTOPLUS 2004 RADIAL CABO 2013 RADIAMI 2005 RADIAL CABO 2013 RADIAMI 2011 Reidy 2004 RIFLE-STEACS 2012 RIVAL 2011 SAFARH-STEMI 2020 Scherthaner 2018 Slagboom 2005 STEM-RADIAL 2013 SUFF 2019 TEMPURA 2003 Wang 2012 Yan 2008	Radii Events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	al <u>Total</u> 300 300 300 300 408 408 0 50 200 200 200 200 200 200 2	Fermo Events 0 1 1 0 0 0 0 1 1 1 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0	ral Total 300 155 428 0 0 0 0 0 0 0 0 0 0 0 0 0	Weight 1.3% 1.2% 1.2% 1.3% 1.4% 26.7% 2.3% 1.3% 5.7% 38.4% 1.3% 1.3% 4.0% 1.2%	Risk Ratio Not estimable 0.34 (0.01, 8.28) 0.35 (0.01, 8.56) Not estimable Not estimable Not estimable 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) 0.33 (0.01, 8.16) Not estimable Not estimable Not estimable Not estimable 0.40 (0.02, 9.60) Not estimable 0.33 (0.01, 7.96) Not estimable 0.33 (0.01, 7.96) Not estimable 0.33 (0.01, 8.10) Not estimable 0.33 (0.01, 7.96) Not estimable 0.33 (0.01, 8.10) Not estimable 0.33 (0.01, 8.10) Not estimable 0.33 (0.01, 8.10) Not estimable 0.33 (0.01, 8.10) 0.33 (0.01, 8.10) 0.33 (0.01, 8.10) 0.33 (0.01, 8.10) 0.33 (0.01, 8.10) Not estimable 0.59 (0.12, 4.00) 0.33 (0.01, 7.96) Not estimable Not estimable	Risk Ratio M-H, Random, 95% CI

Total (95% CI) 12830 12924 100.0% 1.10 [0.77, 1.57] 0.01 0.1 Favours RADIAL 10 Favours FEM

Figure 3. Risk of MACE (A) and major vascular complications (B) at follow-up: radial vs. femoral, in whole group of patients. Risk of myocardial infarction (C) and stroke (D) at follow-up: radial vs. Femoral, in whole group of patients.

4.2.2. Major Vascular Complications

Major vascular complications were reported in 27/34 RCTs, having occurred in 148 patients (1.1%) assigned to the radial approach and in 399 patients (2.9%) assigned to the femoral approach at the latest follow-up. Major vascular complications were fewer in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.37; 95% CI: 0.29 to 0.48; *p* < 0.00001, Figure 3B). The heterogeneity was moderate $(I^2 = 21\%).$

4.2.3. Myocardial Infarction

Myocardial infarction was reported in 29/34 RCTs, occurring in 422 patients (3.1%) assigned to the radial approach and in 462 patients (3.3%) assigned to the femoral approach at the latest follow-up. Myocardial infarction was not different between patients assigned

to the radial approach compared to those assigned to the femoral approach (RR: 0.92; 95% CI: 0.81 to 1.05; p = 0.20, Figure 3C). There was no evidence for heterogeneity across the RCTs (I² = 0%).

4.2.4. Stroke

Stroke was reported in 22/34 RCTs, having occurred in 62 patients (0.5%) assigned to the radial approach and in 58 patients (0.45%) assigned to the femoral approach at the latest follow-up. Stroke was not different between patients assigned to the radial approach compared to those assigned to femoral approach (RR: 1.10; 95% CI: 0.77 to 1.57; p = 0.60, Figure 3D). There was no evidence for heterogeneity across the RCTs (I² = 0%).

5. Results

5.1. Outcomes of Patients with Acute Coronary Syndrome (ACS)

From the 34 RCTs included in this meta-analysis, 18 RCTs included patients with ACS.

5.1.1. Primary Clinical Outcomes

All-Cause Mortality

All-cause mortality was reported in all 18 trials. All-cause mortality occurred in 179 patients (1.7%) assigned to the radial approach and in 245 patients (2.3%) assigned to the femoral approach at the latest follow-up. All-cause mortality was lower in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.73; 95% CI: 0.61 to 0.89; p = 0.001, Supplementary Figure S1a). There was no evidence for heterogeneity across the RCTs ($I^2 = 0\%$).

Major Bleeding

Major bleeding was reported in 17/18 RCTs, having occurred in 573 patients (5.1%) assigned to the radial approach and in 984 patients (9.3%) assigned to the femoral approach. Major bleeding occurred lessoften in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.63; 95% CI: 0.57 to 0.70; p < 0.00001, Supplementary Figure S1b). The heterogeneity was moderate (I² = 37%).

5.1.2. Secondary Clinical Outcomes

MACE

MACE was reported in all 18 included RCTs, in which 542 patients (6.7%) were assigned to the radial approach and 657 patients (8%)were assigned to the femoral approach at the latest follow-up. MACE were fewer in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.83; 95% CI: 0.74 to 0.92; p = 0.0007, Supplementary Figure S2a). There was no evidence for heterogeneity across the RCTs ($I^2 = 0\%$).

Major Vascular Complications

Major vascular complications were reported in 16/18 RCTs, having occurred in 132 patients (1.3%) assigned to the radial approach and 308 patients (2.9%) assigned to the femoral approach at the latest follow-up. Major vascular complications were less in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.44; 95% CI: 0.36 to 0.53; p < 0.00001, Supplementary Figure S2b). The heterogeneity was moderate (I² = 27%).

Myocardial Infarction

Myocardial infarction was reported in 17/18 RCTs, having occurred in 392 patients (3.7%) assigned to the radial approach and in 432 patients (4.1%) assigned to the femoral approach at the latest follow-up. Myocardial infarction was not different between patients assigned to the radial compared to the femoral approach (RR: 0.91; 95% CI: 0.80 to 1.04;

p = 0.17, Supplementary Figure S2c). There was no evidence for heterogeneity across the RCTs (I² = 0%).

Stroke

Stroke was reported in 11/18 included RCTs. Stroke occurred in 62 patients (0.6%) assigned to the radial approach and in 51 patients (0.5%) assigned to the femoral approach at the latest follow-up. Stroke was not different between patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 1.22; 95% CI: 0.85 to 1.76; p = 0.29, Supplementary Figure S2d). There was no evidence for heterogeneity across the RCTs (I² = 0%).

5.2. Outcomes of Patients with STEMI

Of the 34 RCTs included in this meta-analysis, 14 RCTs had patients with STEMI.

5.2.1. Primary Clinical Outcomes

All-Cause Mortality

All-cause mortality was reported in all 14 trials, having occurred in 124 patients (2.3%) assigned to the radial approach and in 181 patients (3.2%) assigned to the femoral approach at the latest follow-up. All-cause mortality was lower in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.69; 95% CI: 0.56 to 0.87; p = 0.001, Supplementary Figure S3a). There was no evidence for heterogeneity across the RCTs (I² = 0%).

Major Bleeding

Major bleeding was reported in all 14 included RCTs, with 46 patients (1.3%) assigned to radial approach and 95 patients (2.7%) assigned to femoral approach at the latest followup. Major bleeding was lower in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.57; 95% CI: 0.51 to 0.64; p < 0.00001, Supplementary Figure S3b). There was no evidence for heterogeneity across the RCTs ($I^2 = 0\%$).

5.2.2. Secondary Clinical Outcomes

MACE

MACE was reported in all 14 included RCTs, having occurred in 265 patients (4.8%) assigned to the radial approach and in 319 patients (5.7%) assigned to the femoral approach at the latest follow-up. MACE was less in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.84; 95% CI: 0.72 to 0.98; p = 0.03, Supplementary Figure S4a). There was no evidence for heterogeneity across the RCTs ($I^2 = 0\%$).

Major Vascular Complications

Major vascular complications were reported in 13/14 RCTs, with 71 patients (2.1%) assigned to the radial approach and 148 patients (4.2%) assigned to the femoral approach at the latest follow-up. Major vascular complications were fewer in patients assigned to the radial approach compared to those assigned to the femoral approach (RR: 0.48; 95% CI: 0.37 to 0.62; p < 0.00001, Supplementary Figure S4b). The heterogeneity was moderate ($I^2 = 31\%$).

Myocardial Infarction

Myocardial infarction was reported in 13/14 RCTs, having occurred in 33 patients (1.3%) assigned to the radial approach and in 35 patients (1.4%) assigned to the femoral approach at the latest follow-up. Myocardial infarction was not different between patients assigned to the radial compared to the femoral approach (RR: 0.92; 95% CI: 0.80 to 1.04; p = 0.19, Supplementary Figure S4c). There was no evidence for heterogeneity across the RCTs ($I^2 = 0\%$).

Stroke

Stroke was reported in 10/14 included RCTs, with 19 patients (0.8%) assigned to the radial approach and 14 patients (0.6%) assigned to the femoral approach at the latest follow-up. Stroke was not different between patients assigned to the radial compared to the femoral approach (RR: 1.25; 95% CI: 0.86 to 1.80; p = 0.24, Supplementary Figure S4d). There was no evidence for heterogeneity across the RCTs (I² = 0%).

5.2.3. Risk of Bias Assessment

The assessment of risk of bias and applicability concerns based on the Quality Assessment of Diagnostic Accuracy Studies questionnaire (QUADAS-2) was used for our study questions [8]. All of the criteria domains for risk of bias and applicability were analyzed. The risk of bias was assessed as "low risk," "high risk," or "unclear risk". Most studies had high a quality (high or moderate level) and clearly defined objectives and main outcomes (Supplementary Figure S5). All domains had low risk of bias (<20%) and no evidence for publication bias based on the Egger's test.

6. Discussion

6.1. Findings

This systematic review and meta-analysis consisted of 34 RCTs with 29,352 patients undergoing diagnostic CA for suspected significant stenotic CAD, including those who underwent PCI, if it was indicated. Included patients were randomized to either the radial or femoral approach. The main findings of this meta-analysis are as follows. (1) The use of radial access compared with femoral access was associated with a significant 26% relative risk reduction in all-cause mortality and 47% relative risk reduction in major bleeding in all patients undergoing CA. The risk reduction was also demonstrated irrespective of the clinical presentation of ACS (27% and 37%, respectively) or STEMI (31% and 43%, respectively). (2) The use of radial access was associated with 18% fewer MACE and 63% fewermajor vascular complications. Again, the radial approach was associated with lower risk of MACE, irrespective of clinical presentation of ACS (17% and 56%, respectively) or STEMI (16% and 52%, respectively) (Figure 4). (3) There was no significant difference in myocardial infarction and stroke between patients assigned to radial approachwith respect to those assigned to the femoral approach in the two subgroups with ACS or STEMI (Figure 4).



Figure 4. Summary of outcome in all study groups.

6.2. Data Interpretation

Coronary angiography and PCI procedures are used in the diagnosis and management of CAD [49]. The traditional approach for CA and PCI, from their introduction, has been through the femoral artery, based on the easy access it offers due to the large caliber [3]. The transfemoral approach for CA and PCI gained widespread acceptance by operators because of the following advantages: long history of use, easy technicality, and the ability of clinicians to use larger catheters and equipment for various interventions [50]. However, the femoral catheterization approach has some disadvantages, including the need for patients' prolonged bed rest, which could be associated with back pain, urinary retention, and neuropathy, particularly in the elderly [6,51,52], as well as prolonged arterial compression related complications, e.g., peripheral ischemia. These limitations promptedcardiologists to explore attempting the trans-radial approach as an alternative, with the first procedure performed in 1989 by Campeau [6], which demonstrated excellent results. Since then, trans-radial catheterization has been an attractive option for both operators and patients, despite the need for prolonged training for optimum skill development. Furthermore, it has also been reported that the trans-radial approach to CA and PCI carries significantly fewervascular complications, including pseudoaneurysms, arteriovenous fistulas, bleeding, and retroperitoneal hematomas, compared with the transfemoral approach [28].

Such advantages could be explained on the basis of reduced limb-threatening ischemia, less need for lying flat (e.g., due to back pain, obesity, or congestive heart failure), and earlier patient discharge. The reduced limb-threatening ischemia could be explained on the basis of a lower likelihood of radial atherosclerosis disease, which is disease known to affect femoral arteries [53]. The technique also does not cross the descending and thoracic aorta, which are known for their involvement in the process of atherosclerosis; hence, this process does not involve the potential thromboembolic complications of the femoral approach [53]. On the other hand, the main limitations of the trans-radial approach are the relatively smaller caliber [54], potential technical challenges in some patients, potential vessel spasm [54], longer procedure time requiring higher radiation [55] and a steep learning curve [56,57]. Despite these limitations, data from the last decades support the use of radial access as the default approach for CA and PCI in the whole spectrum of patients with suspected CAD who are undergoing invasive diagnosis and PCI.

The results of our meta-analysis explain objectively the strong support of the change from the traditional "femoral first" paradigm to the "radial first" approach. In particular, the significantly lower levels of all-cause mortality and major bleeding with the radial approach compared to the femoral approach addresses the controversial findings between the two approaches ([42,43,48,58] and [43,48], respectively) as well as other clinical outcomes [42,43,48,58]. Our findings also support the use of the trans-radial approach even in patients with ACS and STEMI, in whom serious complications proved to be significantly reduced compared to the femoral approach, despite the results of the recently published SAFARI-STEMI RCT [47], which showed comparable outcomes in both approaches.

6.3. Clinical Implications

Our meta-analysis supports the current European Society of Cardiology recommendations that trans-radial coronary artery catheterization is the default procedure unless other technical or anatomical limitations require the use of the alternative femoral approach. The associated lower clinical risk, including MACE and mortality, further supports the trans-radial coronary catheterization approach.

6.4. Limitations

As is the case with all meta-analyses, we relied on the published data from randomized clinical trials, so we did not have any hand in the accuracy of the data collection; however, there is no reason to doubt the high scientific level of these trials. If there were weaknesses in one of the RCTs, this did not seem to have any significant impact on the overall results of the meta-analysis. The over 14,000 patients randomized to each investigation arm—

transfemoral and trans-radial—strengthen the analysis results and demonstrate consistently strong findings. Comparing the overall meta-analysis findings with some individual RCT results could show differences; however, such analyses should be considered as strong evidence over and above individual studies, irrespective of their size. Another conflicting opinion is the relationship between bleeding events and the use of different antithrombotic/anticoagulation protocols [58–62] in patients undergoing radial versus femoral approaches. These protocols should not affect the results of our meta-analysis, as all included studies were RCTs.

6.5. Conclusions

The results of this meta-analysis support the superior clinical safety of using transradial coronary artery catheterization, with or without intervention, over and above the traditional transfemoral approach.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/jcm10102163/s1, Figure S1: Risk of all-cause mortality (A) and major bleeding (B) at follow-up: Radial vs. Femoral, in patients with acute coronary syndrome, Figure S2: Risk of MACE (A) and major vascular complications (B) at follow-up: Radial vs. Femoral, in patients with acute coronary syndrome. Risk of myocardial infarction (C) and stroke (D) at follow-up: Radial vs. Femoral, in patients with acute coronary syndrome, Figure S3: Risk of all causes mortality (A) and major bleeding (B) at follow-up: Radial vs. Femoral, in patients with STEMI, Figure S4: Risk of MACE (A) and major vascular complications (B) at follow-up: Radial vs. Femoral, in patients with STEMI. Risk of myocardial infarction (C) and stroke (D) at follow-up: Radial vs. Femoral, in patients with STEMI, Figure S5: Risk of bias pf the included studies, Table S1: Main clinical, angiographic and procedural characteristics of the included studies.

Author Contributions: G.B. and M.Y.H., designed and drafted the article; G.B., Z.R., and M.Y.H. performed the literature search, study selection and data extraction. G.B., A.B. (Artan Bajraktari), I.B., F.Z.-B. and M.Y.H., analyzed and interpreted the data; M.Y.H., G.B. A.B. (Arlind Batalli), and S.E. critically revised the article. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Neumann, F.-J.; Sousa-Uva, M.; Ahlsson, A.; Alfonso, F.; Banning, A.P.; Benedetto, U.; Byrne, R.A.; Collet, J.-P.; Falk, V.; Head, S.J.; et al. 2018 ESC/EACTS guidelines on myocardial revascularization. *Russ. J. Cardiol.* 2019, 40, 87–165. [CrossRef]
- Habib, R.H.; Dimitrova, K.R.; Badour, S.A.; Yammine, M.B.; El-Hage-Sleiman, A.K.M.; Hoffman, D.M.; Geller, C.M.; Schwann, T.A.; Tranbaugh, R.F. CABG Versus PCI: Greater Benefit in Long-Term Outcomes with Multiple Arterial Bypass Grafting. J. Am. Coll. Cardiol. 2015, 66, 1417–1427. [CrossRef]
- Venkitachalam, L.; Kip, K.E.; Selzer, F.; Wilensky, R.L.; Slater, J.; Mulukutla, S.R.; Marroquin, O.C.; Block, P.C.; Williams, D.O.; Kelsey, S.F. Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: A report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985–1986 PTCA and 1997–2006 dynamic registries. *Circ. Cardiovasc. Interv.* 2009, 2, 6–13. [CrossRef]
- Rao, S.V.; O'Grady, K.; Pieper, K.S.; Granger, C.B.; Newby, L.K.; Van de Werf, F.; Mahaffey, K.W.; Califf, R.M.; Harrington, R.A. Impact of Bleeding Severity on Clinical Outcomes Among Patients With Acute Coronary Syndromes. *Am. J. Cardiol.* 2005, *96*, 1200–1206. [CrossRef]
- Chhatriwalla, A.K.; Amin, A.P.; Kennedy, K.F.; House, J.A.; Cohen, D.J.; Rao, S.V.; Messenger, J.C.; Marso, S.P.; Registry, F.T.N.C.D. Association Between Bleeding Events and In-hospital Mortality After Percutaneous Coronary Intervention. *JAMA* 2013, 309, 1022–1029. [CrossRef]
- 6. Campeau, L. Percutaneous radial artery approach for coronary angiography. Catheter. Cardiovasc. Diagn. 1989, 16, 3–7. [CrossRef]

- Hildick-Smith, D.J.; Lowe, M.D.; Walsh, J.T.; Ludman, P.F.; Stephens, N.G.; Schofield, P.M.; Stone, D.L.; Shapiro, L.M.; Petch, M.C. Coronary angiography from the radial artery—Experience, complications and limitations. *Int. J. Cardiol.* 1998, 64, 231–239. [CrossRef]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ* 2009, 339, b2535. [CrossRef]
- Bovill, E.G.; Terrin, M.L.; Stump, D.C.; Berke, A.D.; Frederick, M.; Collen, D.; Feit, F.; Gore, J.M.; Hillis, L.D.; Lambrew, C.T.; et al. Hemorrhagicevents during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. *Ann. Intern. Med.* **1991**, 115, 256–265. [CrossRef] [PubMed]
- Mehran, R.; Rao, S.V.; Bhatt, D.L.; Gibson, C.M.; Caixeta, A.; Eikelboom, J.; Kaul, S.; Wiviott, S.D.; Menon, V.; Nikolsky, E.; et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011, 123, 2736–2747. [CrossRef]
- 11. Green, S. Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0 [Updated March 2011]; The Cochrane Collaboration: London, UK, 2011.
- 12. Cooper, H.M.; Hedges, L.V. The Handbook of Research Synthesis; Russell Sage Foundation: New York, NY, USA, 1994.
- 13. Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med. Res. Methodol.* **2005**, *5*, 13. [CrossRef] [PubMed]
- 14. Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. *BMJ* **2003**, 327, 557–560. [CrossRef] [PubMed]
- Kiemeneij, F.; Laarman, G.J.; Odekerken, D.; Slagboom, T.; van der Wieken, R. A Randomized Comparison of Percutaneous Transluminal Coronary Angioplasty by the Radial, Brachial and Femoral Approaches: The Access Study. *J. Am. Coll. Cardiol.* 1997, 29, 1269–1275. [CrossRef]
- 16. Benit, E.; Missault, L.; Eeman, T.; Carlier, M.; Muyldermans, L.; Materne, P.; Lafontaine, P.; De Keyser, J.; DeCoster, O.; Pourbaix, S.; et al. Brachial, radial, or femoral approach for elective Palmaz-Schatz stent implantation: A randomized comparison. *Catheter. Cardiovasc. Diagn.* **1997**, *41*, 124–130. [CrossRef]
- 17. Mann, T.; Cubeddu, G.; Bowen, J.; Schneider, J.E.; Arrowood, M.; Newman, W.N.; Zellinger, M.J.; Rose, G.C. Stenting in acute coronary syndromes: A comparison of radial versus femoral access sites. *J. Am. Coll. Cardiol.* **1998**, *32*, 572–576. [CrossRef]
- 18. Cooper, C.J.; El-Shiekh, R.A.; Cohen, D.J.; Blaesing, L.; Burket, M.W.; Basu, A.; Moore, J.A. Effect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison. *Am Heart J.* **1999**, *138 Pt* 1, 430–436. [CrossRef]
- Saito, S.; Tanaka, S.; Hiroe, Y.; Miyashita, Y.; Takahashi, S.; Tanaka, K.; Satake, S. Comparative study on transradial approach vs. transfemoral approach in primary stent implantation for patients with acute myocardial infarction: Results of the test for myocardial infarction by prospective unicenter randomization for access sites (TEMPURA) trial. *Catheter. Cardiovasc. Interv.* 2003, 59, 26–33. [CrossRef] [PubMed]
- Reddy, B.K.; Brewster, P.S.; Walsh, T.; Burket, M.W.; Thomas, W.J.; Cooper, C.J. Randomized comparison of rapid ambulation using radial, 4 French femoral access, or femoral access with AngioSeal closure. *Catheter. Cardiovasc. Interv.* 2004, 62, 143–149. [CrossRef] [PubMed]
- Louvard, Y.; Benamer, H.; Garot, P.; Hildick-Smith, D.; Loubeyre, C.; Rigattieri, S.; Monchi, M.; Lefèvre, T.; Hamon, M. Comparison of transradial and transfemoral approaches for coronary angiography and angioplasty in octogenarians (the OCTOPLUS study). *Am. J. Cardiol.* 2004, *94*, 1177–1180. [CrossRef] [PubMed]
- 22. Slagboom, T.; Kiemeneij, F.; Laarman, G.J.; Van Der Wieken, R. Outpatient coronary angioplasty: Feasible and safe. *Catheter. Cardiovasc. Interv.* 2005, *64*, 421–427. [CrossRef]
- Cantor, W.J.; Puley, G.; Natarajan, M.K.; Dzavik, V.; Madan, M.; Fry, A.; Kim, H.H.; Velianou, J.L.; Pirani, N.; Strauss, B.H.; et al. Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial. *Am. Heart J.* 2005, *150*, 543–549. [CrossRef]
- 24. Brasselet, C.; Tassan, S.; Nazeyrollas, P.; Hamon, M.; Metz, D. Randomised comparison of femoral versus radial approach for percutaneous coronary intervention using abciximab in acute myocardial infarction: Results of the FARMI Trial. *Heart* 2006, *93*, 1556–1561. [CrossRef]
- Yan, Z.-X.; Zhou, Y.-J.; Zhao, Y.-X.; Liu, Y.-Y.; Shi, D.-M.; Guo, Y.-H.; Cheng, W.-J. Safety and feasibility of transradial approach for primary percutaneous coronary intervention in elderly patients with acute myocardial infarction. *Chin. Med. J.* 2008, 121, 782–786. [CrossRef]
- Achenbach, S.; Ropers, D.; Kallert, L.; Turan, N.; Krähner, R.; Wolf, T.; Garlichs, C.; Flachskampf, F.; Daniel, W.G.; Ludwig, J. Transradial versus transfemoral approach for coronary angiography and intervention in patients above 75 years of age. *Catheter. Cardiovasc. Interv.* 2008, 72, 629–635. [CrossRef] [PubMed]
- 27. Santas, E.; Bodí, V.; Sanchis, J.; Núñez, J.; Mainar, L.; Miñana, G.; Chorro, F.J.; Llácer, A. The left radial approach in daily practice. A randomized study comparing femoral and right and left radial approaches. *Rev. Española Cardiol.* 2009, *62*, 482–490. [CrossRef]
- Brueck, M.; Bandorski, D.; Kramer, W.; Wieczorek, M.; Höltgen, R.; Tillmanns, H. A Randomized Comparison of Transradial Versus Transfemoral Approach for Coronary Angiography and Angioplasty. *JACC Cardiovasc. Interv.* 2009, 2, 1047–1054. [CrossRef]

- 29. Gan, L.; Li, Q.; Liu, R.; Zhao, Y.; Qiu, J.; Liao, Y. Effectiveness and feasibility of transradial approaches for primary percutaneous coronary intervention in patients with acute myocardial infarction. *J. Nanjing Med Univ.* **2009**, *23*, 270–274. [CrossRef]
- Chodór, P.; Krupa, H.; Kurek, T.; Sokal, A.; Swierad, M.; Was, T.; Streb, W.; Duszańska, A.; Swiatkowski, A.; Honisz, G.; et al. RADIal versus femoral approach for percutaneous coronary interventions in patients with Acute Myocardial Infarction (RADIAMI): A prospective, randomized, single-center clinical trial. *Cardiol. J.* 2009, *16*, 332–340. [PubMed]
- 31. Hou, L.; Wei, Y.-D.; Li, W.-M.; Xu, Y.-W. Comparative study on transradial versus transfemoral approach for primary percutaneous coronary intervention in Chinese patients with acute myocardial infarction. *Saudi Med. J.* **2010**, *31*, 158–162. [PubMed]
- Ziakas, A.G.; Koskinas, K.C.; Gavrilidis, S.; Giannoglou, G.D.; Hadjimiltiades, S.; Gourassas, I.; Theofilogiannakos, E.; Economou, F.; Styliadis, I. Radial versus femoral access for orally anticoagulated patients. *Catheter. Cardiovasc. Interv.* 2010, 76, 493–499. [CrossRef] [PubMed]
- 33. Jolly, S.S.; Yusuf, S.; Cairns, J.; Niemelä, K.; Xavier, D.; Widimsky, P.; Budaj, A.; Niemelä, M.; Valentin, V.; Lewis, B.S.; et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): A randomised, parallel group, multicentre trial. *Lancet* 2011, 377, 1409–1420. [CrossRef]
- 34. Chodór, P.; Kurek, T.; Kowalczuk, A.; Świerad, M.; Wąs, T.; Honisz, G.; Świątkowski, A.; Streb, W.; Kalarus, Z. Radial vs femoral approach with StarClose clip placement for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. RADIAMI II: A prospective, randomised, single centre trial. *Kardiol. Pol.* 2011, 69, 763–771. [PubMed]
- 35. Romagnoli, E.; Biondi-Zoccai, G.; Sciahbasi, A.; Politi, L.; Rigattieri, S.; Pendenza, G.; Summaria, F.; Patrizi, R.; Borghi, A.; Di Russo, C.; et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: The RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. *J. Am. Coll Cardiol.* 2012, 60, 2481–2489. [CrossRef] [PubMed]
- Wang, Y.-B.; Fu, X.-H.; Wang, X.-C.; Gu, X.-S.; Zhao, Y.-J.; Hao, G.-Z.; Jiang, Y.-F.; Li, S.-Q.; Wu, W.-L.; Fan, W.-Z. Randomized comparison of radial versus femoral approach for patients with STEMI undergoing early PCI following intravenous thrombolysis. *J. Invasive Cardiol.* 2012, 24, 412–416. [PubMed]
- Michael, T.T.; Alomar, M.; Papayannis, A.; Mogabgab, O.; Patel, V.G.; Rangan, B.V.; Luna, M.; Hastings, J.L.; Grodin, J.; Abdullah, S.; et al. A randomized comparison of the transradial and transfemoral approaches for coronary artery bypass graft angiography and intervention: The RADIAL-CABG Trial (RADIAL Versus Femoral Access for Coronary Artery Bypass Graft Angiography and Intervention). *JACC Cardiovasc. Interv.* 2013, *6*, 1138–1144. [CrossRef] [PubMed]
- 38. Kołtowski, Ł.; Filipiak, K.J.; Kochman, J.; Pietrasik, A.; Rdzanek, A.; Huczek, Z.; Ścibisz, A.; Mazurek, T.; Opolski, G. Access for percutaneous coronary intervention in ST segment elevation myocardial infarction: Radial vs. femoral—A prospective, randomised clinical trial (OCEAN RACE). *Kardiol. Pol.* **2014**, *72*, 604–611. [CrossRef]
- Aktürk, E.; Kurtoğlu, E.; Ermiş, N.; Açıkgöz, N.; Yağmur, J.; Altuntaş, M.S.; Pekdemir, H.; Özdemir, R. Comparision of pain levels of transradial versus transfemoral coronary catheterization: A prospective and randomized study. *Anadolu Kardiyol. Derg.* 2014, 14, 140–146. [CrossRef]
- 40. Bernat, I.; Horak, D.; Stasek, J.; Mates, M.; Pesek, J.; Ostadal, P.; Hrabos, V.; Dusek, J.; Koza, J.; Sembera, Z.; et al. ST-segment elevation myocardial infarction treated by radial or femoral approach in a multicenter randomized clinical trial: The STEMI-RADIAL trial. *J. Am. Coll Cardiol.* **2014**, *63*, 964–972. [CrossRef] [PubMed]
- Valgimigli, M.; Gagnor, A.; Calabró, P.; Frigoli, E.; Leonardi, S.; Zaro, T.; Rubartelli, P.; Briguori, C.; Andò, G.; Repetto, A.; et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: A randomisedmulticentre trial. *Lancet* 2015, 385, 2465–2476. [CrossRef]
- 42. Fastner, C.; Behnes, M.; Ünsal, M.; El-Battrawy, I.; Ansari, U.; Mashayekhi, K.; Hoffmann, U.; Lang, S.; Kuschyk, J.; Borggrefe, M.; et al. Clinical outcomes of femoral closure compared to radial compression devices following percutaneous coronary intervention: The FERARI study. *Heart Vessel.* **2016**, *32*, 520–530. [CrossRef]
- 43. Andrade, P.B.; Mattos, L.A.; Rinaldi, F.S.; Bienert, I.C.; Barbosa, R.A.; Labrunie, A.; Tebet, M.; Esteves, V.; Abizaid, A.; Sousa, A.R. Comparison of a vascular closure device versus the radial approach to reduce access site complications in non-ST-segment elevation acute coronary syndrome patients: The angio-seal versus the radial approach in acute coronary syndrome trial. *Catheter. Cardiovasc. Interv.* 2016, *89*, 976–982. [CrossRef] [PubMed]
- 44. Bhat, F.A.; Changal, K.H.; Raina, H.; Tramboo, N.A.; Rather, H.A. Transradial versus transfemoral approach for coronary angiography and angioplasty—A prospective, randomized comparison. *BMC Cardiovasc. Disord.* **2017**, *17*, 1–7. [CrossRef] [PubMed]
- 45. Schernthaner, C.; Hammerer, M.; Harb, S.; Heigert, M.; Hoellinger, K.; Lassnig, E.; Maurer, E.; Schuler, J.; Siostrzonek, P.; Ulmer, H.; et al. Radial versus femoral access site for percutaneous coronary intervention in patients suffering acute myocardial infarction. *Wien. Klin. Wochenschr.* **2017**, *130*, 182–189. [CrossRef] [PubMed]
- Koshy, L.M.; Aberle, L.H.; Krucoff, M.W.; Hess, C.N.; Mazzaferri, E., Jr.; Jolly, S.S.; Jacobs, A.; Gibson, C.M.; Mehran, R.; Gilchrist, I.C.; et al. Comparison of Radial Access, Guided Femoral Access, and Non-Guided Femoral Access Among Women Undergoing Percutaneous Coronary Intervention. J. Invasive Cardiol. 2018, 30, 18–22.
- 47. Nguyen, P.; Makris, A.; Hennessy, A.; Jayanti, S.; Wang, A.; Park, K.; Chen, V.; Nguyen, T.; Lo, S.; Xuan, W.; et al. Standard versus ultrasound-guided radial and femoral access in coronary angiography and intervention (SURF): A randomised controlled trial. *EuroIntervention* **2019**, *15*, e522–e530. [CrossRef]

- May, M.L.; Wells, G.; So, D.; Chong, A.Y.; Dick, A.; Froeschl, M.; Glover, C.; Hibbert, B.; Marquis, J.F.; Blondeau, M.; et al. Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction: The SAFARI-STEMI Randomized Clinical Trial. *JAMA Cardiol.* 2020, *5*, 126–134. [CrossRef] [PubMed]
- 49. Wensley, C.J.; Kent, B.; McAleer, M.B.; Savage, S.M.; Stewart, J.T. Pain relief for the removal of femoral sheath after percutaneous coronary intervention. *Cochrane Database Syst. Rev.* **2008**, 2008, CD006043. [CrossRef]
- 50. Kolkailah, A.A.; Alreshq, R.S.; Muhammed, A.M.; Zahran, M.E.; El-Wegoud, M.A.; Nabhan, A.F. Transradial versus transfemoral approach for diagnostic coronary angiography and percutaneous coronary intervention in people with coronary artery disease. *Cochrane Database Syst. Rev.* 2018, 2018, CD012318. [CrossRef]
- 51. Tavakol, M.; Ashraf, S.; Brener, S.J. Risks and Complications of Coronary Angiography: A Comprehensive Review. *Glob. J. Health Sci.* **2012**, *4*, 65–93. [CrossRef]
- Dal Molin, A.; Faggiano, F.; Bertoncini, F.; Buratti, G.; Busca, E.; Casarotto, R.; Gaboardi, S.; Allara, E. Bed rest for preventing complications after transfemoral cardiac catheterisation: A protocol of systematic review and network meta-analysis. *Syst. Rev.* 2015, *4*, 47. [CrossRef]
- Kasapis, C.; Gurm, H.S. Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review. Curr. Cardiol. Rev. 2009, 5, 296–311. [CrossRef] [PubMed]
- 54. Kim, J.-Y.; Yoon, J. Transradial Approach as a Default Route in Coronary Artery Interventions. *Korean Circ. J.* **2011**, *41*, 1–8. [CrossRef]
- 55. Brasselet, C.; Blanpain, T.; Tassan-Mangina, S.; Deschildre, A.; Duval, S.; Vitry, F.; Gaillot-Petit, N.; Clément, J.P.; Metz, D. Comparison of operator radiation exposure with optimized radiation protection devices during coronary angiograms and ad hoc percutaneous coronary interventions by radial and femoral routes. *Eur. Heart J.* **2007**, *29*, 63–70. [CrossRef] [PubMed]
- Hess, C.N.; Peterson, E.D.; Neely, M.L.; Dai, D.; Hillegass, W.B.; Krucoff, M.W.; Kutcher, M.A.; Messenger, J.C.; Pancholy, S.; Piana, R.N.; et al. The Learning Curve for Transradial Percutaneous Coronary Intervention among Operators in the United States. *Circulation* 2014, 129, 2277–2286. [CrossRef]
- 57. Hamon, M.; Pristipino, C.; Di Mario, C.; Nolan, J.; Ludwig, J.; Tubaro, M.; Sabaté, M.; Mauri-Ferré, J.; Huber, K.; Niemelä, K.; et al. Consensus document on the radial approach in percutaneous cardiovascular interventions: Position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. *EuroIntervention* 2013, *8*, 1242–1251. [CrossRef]
- 58. Valgimigli, M.; Frigoli, E.; Leonardi, S.; Vranckx, P.; Rothenbühler, M.; Tebaldi, M.; Varbella, F.; Calabrò, P.; Garducci, S.; Rubartelli, P.; et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): Final 1-year results of a multicentre, randomised controlled trial. *Lancet* 2018, 392, 835–848. [CrossRef]
- Cayla, G.; Silvain, J.; Barthelemy, O.; Connor, S.O.; Payot, L.; Bellemain-Appaix, A.; Beygui, F.; Aout, M.; Collet, J.-P.; Vicaut, E.; et al. Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: An analysis of major bleeding complications in the ABOARD Study. *Heart* 2011, *97*, 887–891. [CrossRef] [PubMed]
- 60. Gargiulo, G.; Valgimigli, M.; Sunnåker, M.; Vranckx, P.; Frigoli, E.; Leonardi, S.; Spirito, A.; Gragnano, F.; Manavifar, N.; Galea, R.; et al. Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. *Rev. Española Cardiol.* **2020**, *73*, 893–901. [CrossRef]
- Alexopoulos, D.; Xanthopoulou, I.; Deftereos, S.; Sitafidis, G.; Kanakakis, I.; Hamilos, M.; Karayannis, G.; Angelidis, C.; Stavrou, K.; Vavuranakis, M.; et al. Bivalirudin Use and One-Month Outcome in the Context of Contemporary Antiplatelet Treatment: Insights from the Greek Antiplatelet Registry. *Cardiovasc. Ther.* 2014, *32*, 120–126. [CrossRef]
- Vora, A.N.; Peterson, E.D.; McCoy, L.A.; Garratt, K.N.; Kutcher, M.A.; Marso, S.P.; Roe, M.T.; Messenger, J.C.; Rao, S.V. The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry CathPCI Registry. *JACC Cardiovasc. Interv.* 2016, *9*, 771–779. [CrossRef] [PubMed]